StockData
enVVeno Medical Corp logo

enVVeno Medical Corp (NVNO) shareholders

NVNONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 6/30
$5.77+0.00 (0.00%)

Close on Nov 18, 2026Market cap $4.01MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
12.8%
0M of 1M shares
Institutional holders
17
3 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 4 sales
Net sold $4.94K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Perceptive Advisors LLC
Joint filing with Joseph Edelman (9.99%), Perceptive Life Sciences Master Fund, Ltd. (9.99%)
2,048,5159.99%13G (passive) amendmentDec 31, 2025
Mark Kingdon
Joint filing with Kingdon Capital Management, L.L.C. (7.10%), M. Kingdon Offshore Master Fund, L.P. (6.60%) and 1 more
1,359,2617.10%13G (passive)Sep 2, 2025
Nantahala Capital Management, LLC
Joint filing with Wilmot B. Harkey (7.06%), Daniel Mack (7.06%)
1,285,8577.06%13G (passive) amendmentSep 30, 2024
Perceptive Life Sciences Master Fund, Ltd.
Joint filing with Perceptive Advisors LLC (9.99%), Joseph Edelman (9.99%)
68,5259.99%13G (passive) amendmentMar 31, 2026
Kingdon Capital Management, L.L.C.
Joint filing with M. Kingdon Offshore Master Fund, L.P. (5.50%), Kingdon GP, LLC (5.50%) and 1 more
36,1665.50%13G (passive) amendmentMar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NVNOValueChange% of portfolio
Kingdon Capital Management, L.L.C.36,1665.21%$387.34K–0.04%
CM Management, LLC35,7145.14%$382.50K–0.25%
Vanguard Capital Management LLC6,2870.90%$67.40K–0.00%
JPMorgan Chase & Co5,2080.75%$59.11K−10.00%
Vanguard Fiduciary Trust Co2,1840.31%$23.41K–0.00%
Westside Investment Management, Inc.1,5250.22%$16.33K−640.00%
Mirae Asset Global Investments Co., Ltd.5390.08%$5.77KNew0.00%
BlackRock, Inc.4140.06%$4.43K−1,4260.00%
Tower Research Capital LLC (TRC)3310.05%$3.55K−2110.00%
Wells Fargo & Company/Mn1140.02%$1.22K–0.00%
Allied Private Wealth LLC880.01%$978New0.00%
Vanguard Global Advisers, LLC770.01%$825–0.00%
Morgan Stanley590.01%$632−170.00%
Osaic Holdings, Inc.70.00%$74–0.00%
Group One Trading, L.P.20.00%$21–0.00%
Barclays PLC20.00%$21New0.00%
UBS Group AG10.00%$11−2420.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026170M12.8%3 / 06 / 30M0M
Q1 2026170M14.5%17 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of NVNOValue% of fundAs of
Vanguard Extended Market Index Fund6,2870.90%$67.40K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund5,9950.86%$67.92K0.00%May 31, 2026
Fidelity Total Market Index Fund8410.12%$9.53K0.00%May 31, 2026
Fidelity Series Total Market Index Fund8050.12%$9.12K0.00%May 31, 2026
Fidelity Nasdaq Composite Index Fund5850.08%$6.63K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Robert Andrew BermanChief Executive Officer, Director22,2363.20%Dec 18, 2025
Hamed AlaviChief Technology Officer8,3341.20%Dec 18, 2025
Marc H. GlickmanSVP & Chief Medical Officer1,6000.23%Dec 18, 2025
Jennifer BrightChief Financial Officer––May 20, 2025
Francis DuhayDirector2,3510.34%Sep 14, 2026
Matthew JenusaitisDirector16,5452.38%Dec 15, 2025
Robert GrayDirector11,1551.61%Dec 15, 2025
Sanjay ShrivastavaDirector9,2881.34%Dec 15, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Francis Duhay
Director
Sep 11, 2026Sale(10b5-1 plan)−11$11.21$1232,351
Francis Duhay
Director
Jun 11, 2026Sale(10b5-1 plan)−140$10.31$1.44K2,362
Francis Duhay
Director
Mar 12, 2026Sale(10b5-1 plan)−140$11.52$1.61K2,502
Francis Duhay
Director
Dec 11, 2025Sale(10b5-1 plan)−4,900$0.36$1.76K92,544
Francis Duhay
Director
Sep 15, 2025Sale(10b5-1 plan)−4,900$0.83$4.07K97,444
Francis Duhay
Director
Dec 31, 2024Buy+81,433$3.07$250.00K102,344
Robert Gray
Director
Dec 31, 2024Buy+3,500$2.94$10.29K11,155
Sanjay Shrivastava
Director
Dec 24, 2024Buy+5,400$2.90$15.66K9,288
Matthew Jenusaitis
Director
Dec 19, 2024Buy+9,620$2.53$24.34K16,545
Robert Andrew Berman
Chief Executive Officer, Director
Dec 19, 2024Buy+12,000$2.55$30.60K222,236
Hamed Alavi
Chief Technology Officer
Mar 13, 2024Option exercise+8,334$3.59$29.92K8,334
Hamed Alavi
Chief Technology Officer
Mar 13, 2024Sale−8,334$6.22$51.84K0
Robert Gray
Director
Sep 13, 2022Option exercise+1,041––7,655
Matthew Jenusaitis
Director
Sep 13, 2022Option exercise+1,041––6,925
Francis Duhay
Director
Aug 16, 2022Buy+7,751$6.14$47.59K20,911
Sanjay Shrivastava
Director
Jun 30, 2022Buy+1,000$3.85$3.85K3,888
Robert Andrew Berman
Chief Executive Officer, Director
Jun 27, 2022Buy+2,500$3.80$9.50K210,236
Robert Andrew Berman
Chief Executive Officer, Director
Nov 30, 2021Award+200,000––207,736
Craig Glynn
Chief Financial Officer
Nov 30, 2021Award+50,000––50,000
Marc H. Glickman
SVP & Chief Medical Officer
Nov 30, 2021Award+100,000––101,600
Robert Andrew Berman
CEO, Director
Nov 19, 2021Buy+2,000$7.43$14.86K7,736
Robert Andrew Berman
CEO
Nov 16, 2021Buy+2,000$7.87$15.74K5,736
Sanjay Shrivastava
Director
Nov 16, 2021Option exercise+388––2,888
Robert Gray
Director
Sep 13, 2021Option exercise+1,042––6,614
Matthew Jenusaitis
Director
Sep 13, 2021Option exercise+1,042––5,884
Matthew Jenusaitis
Director
Aug 25, 2021Buy+1,300$7.70$10.01K4,842
Robert Gray
Director
Jun 16, 2021Buy+2,000$6.25$12.50K5,572
Marc H. Glickman
SVP & Chief Medical Officer
May 21, 2021Buy+1,600$5.90$9.44K1,600
Robert Andrew Berman
Chief Executive Officer, Director
May 18, 2021Buy+3,000$5.47$16.41K3,736
Francis Duhay
Director
May 17, 2021Buy+9,492$5.33$50.59K13,160
Biodyne Holding, S.A.
–
Aug 21, 2020Sale−75,000$0.38$28.50K1,405,433
Biodyne Holding, S.A.
–
Aug 20, 2020Sale−75,000$0.27$20.25K1,480,433
Biodyne Holding, S.A.
–
Aug 19, 2020Sale−50,000$0.30$15.00K1,555,433
Biodyne Holding, S.A.
–
Aug 18, 2020Sale−50,000$0.34$17.00K1,605,433
Biodyne Holding, S.A.
–
Aug 14, 2020Sale−50,000$0.31$15.50K1,655,433
Biodyne Holding, S.A.
–
Aug 3, 2020Sale−70,000$0.32$22.40K1,705,433
Biodyne Holding, S.A.
–
Jul 31, 2020Sale−5,000$0.34$1.70K1,775,433
Biodyne Holding, S.A.
–
Jul 30, 2020Sale−25,000$0.32$8.00K1,780,433
Biodyne Holding, S.A.
–
Jul 21, 2020Sale−50,000$0.45$22.50K1,805,433
Biodyne Holding, S.A.
–
Jul 20, 2020Sale−150,000$0.43$64.50K1,855,433
Matthew Jenusaitis
Director
Jul 18, 2020Award+62,500––62,500
Robert Gray
Director
Jul 18, 2020Award+62,500––78,250
Sanjay Shrivastava
Director
Jul 18, 2020Award+62,500––97,500
Francis Duhay
Director
Jul 18, 2020Award+62,500––107,228
Biodyne Holding, S.A.
–
Jul 17, 2020Sale−50,000$0.38$19.00K2,005,433
Biodyne Holding, S.A.
–
Jul 16, 2020Sale−50,000$0.38$19.00K2,055,433
Biodyne Holding, S.A.
–
Jul 6, 2020Sale−6,450$0.39$2.52K2,105,433
Biodyne Holding, S.A.
–
Jul 2, 2020Sale−57,000$0.40$22.80K2,111,883
Biodyne Holding, S.A.
–
Jul 1, 2020Sale−45,000$0.38$17.10K2,168,883
Biodyne Holding, S.A.
–
Jun 29, 2020Sale−68,094$0.39$26.56K2,213,883
Biodyne Holding, S.A.
–
Jun 26, 2020Sale−80,000$0.38$30.40K2,281,977
Biodyne Holding, S.A.
–
Jun 25, 2020Sale−100,000$0.40$40.00K2,361,977
Biodyne Holding, S.A.
–
Jun 24, 2020Sale−55,530$0.42$23.32K2,461,977
Biodyne Holding, S.A.
–
Jun 23, 2020Sale−80,000$0.43$34.40K2,517,507
Biodyne Holding, S.A.
–
Jun 22, 2020Sale−63,186$0.46$29.07K2,597,507
Biodyne Holding, S.A.
–
Jun 19, 2020Sale−80,000$0.46$36.80K2,660,693
Biodyne Holding, S.A.
–
Jun 18, 2020Sale−61,640$0.45$27.74K2,740,693
Biodyne Holding, S.A.
–
Jun 17, 2020Sale−203,100$0.48$97.49K2,802,333
Biodyne Holding, S.A.
–
Jun 16, 2020Sale−150,000$0.43$64.50K3,005,433
Biodyne Holding, S.A.
–
Jun 15, 2020Sale−100,000$0.42$42.00K3,155,433

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
3.87%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+104.8%
From 0M shares
Short volume, 20 days
42.7%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of enVVeno Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 46 shares on Sep 3, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Francis Duhay
Director
Sep 11, 202611$123Sep 11, 2026OPEN MARKET PURCHASE
Francis Duhay
Director
Jun 11, 2026140$1.44KJun 11, 2026OPEN MARKET PURCHASE
Francis Duhay
Director
Mar 12, 2026140$1.61KMar 12, 2026OPEN MARKET PURCHASE
Francis Duhay
Director
Sep 15, 20259,800$8.14KSep 15, 2025OPEN MARKET PURCHASE

See a number that looks wrong?